# Chris McNulty

> Chris McNulty is the interim CEO of Ring Therapeutics, a Cambridge, Massachusetts biotech developing genetic medicines that use commensal anelloviruses as delivery vectors. An MIT-trained engineer with a Harvard MBA, he joined Ring in May 2023 as Chief Financial Officer and Head of Corporate Strategy and stepped up to lead the company in December 2024. Over more than 15 years in pharma and biotech finance, he has closed financing transactions worth more than $300 million across companies including VBI Vaccines, InVivo Therapeutics, Repligen, and Genzyme.

- **Role:** Interim CEO at Ring Therapeutics
- **Organizations:** Ring Therapeutics, VBI Vaccines, InVivo Therapeutics, Repligen Corporation, Seventh Sense Biosystems, Genzyme Corporation
- **Nationality:** American
- **Education:** B.S. in Electrical Engineering & Computer Science, Massachusetts Institute of Technology (MIT), Master's in Electrical Engineering & Computer Science, Massachusetts Institute of Technology (MIT), MBA, Harvard Business School
- **Known for:** Completed financing transactions valued at more than $300 million across his career., Led finance efforts for over $50 million in financing at InVivo Therapeutics., Secured $3.3 million in funding at Seventh Sense Biosystems.

## Career timeline

- **Genzyme era** — Held director-level positions at Genzyme Corporation, leading two collaborations in the rare genetic disease space.
- **Repligen era** — Served as Director and Senior Director at Repligen Corporation, overseeing in-licensing and out-licensing including a deal with Biomarin and partnerships with Novozymes and Pfizer.
- **Seventh Sense Biosystems** — Held various director-level positions and secured $3.3 million in funding.
- **InVivo Therapeutics** — Held multiple executive roles including CFO, leading finance efforts for over $50 million of financing.
- **VBI Vaccines** — Served as CFO and Head of Business Development, leading the finance and business development teams.
- **2023-05** — Joined Ring Therapeutics as Chief Financial Officer and Head of Corporate Strategy.
- **2024-12** — Appointed interim CEO of Ring Therapeutics as Tuyen Ong moved into an advisory role.

## Achievements

- Completed financing transactions valued at more than $300 million across his career.
- Led finance efforts for over $50 million in financing at InVivo Therapeutics.
- Secured $3.3 million in funding at Seventh Sense Biosystems.
- Structured licensing deals with major pharmaceutical partners including Biomarin, Novozymes, and Pfizer while at Repligen.
- Rose from CFO to interim CEO of Ring Therapeutics within about 18 months of joining.

## Latest updates

- **2024-12** — Appointed interim CEO of Ring Therapeutics as CEO Tuyen Ong transitioned to an advisory role.
- **2023-05** — Joined Ring Therapeutics as CFO and Head of Corporate Strategy.

## Links

- Website: https://ringtx.com
- LinkedIn: http://www.linkedin.com/in/chris-mcnulty-41527b

---

Profile page: https://yespress.io/chris-mcnulty
Published by YesPress — https://yespress.io
Last updated: 2026-07-22